Localized large cell lymphoma: Is there any need for radiation therapy?

Daniel O. Persky, Thomas P Miller

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Diffuse large B-cell lymphoma is the most common lymphoma diagnosed in the United States and presents as localized disease in about 25% of the patients. The standard of care was established by Southwest Oncology Group trial 8736, which showed the superiority of a short course of chemotherapy followed by radiation over a longer course of chemotherapy alone. This review discusses the studies that followed with the intent to establish whether the standard of care has changed. RECENT FINDINGS: Subsequent studies examined the role of radiation therapy, the number of cycles and intensity of chemotherapy, and addition of rituximab. Interpretation of results has been confounded by patient selection, especially by including patients with bulky stage II disease. Quality of radiation therapy may have diminished its efficacy in some of the studies. Concurrent administration of rituximab provided a more modest improvement as compared with advanced disease setting. Attempts are now made to use PET scans to eliminate the need for radiation therapy in some patients. SUMMARY: Radiation therapy remains useful when administered expediently and as initially described, but PET scans successfully define a subset of patients who do not benefit from radiation. Using a longer or more intensive course of rituximab-containing chemotherapy without radiation has never been compared to combined modality treatment and remains investigational.

Original languageEnglish (US)
Pages (from-to)401-406
Number of pages6
JournalCurrent Opinion in Oncology
Volume21
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Lymphoma
Radiotherapy
Drug Therapy
Radiation
Standard of Care
Positron-Emission Tomography
Investigational Therapies
Lymphoma, Large B-Cell, Diffuse
Patient Selection
Rituximab

Keywords

  • Aggressive lymphoma
  • Diffuse large B-cell lymphoma
  • Early-stage
  • Localized
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Localized large cell lymphoma : Is there any need for radiation therapy? / Persky, Daniel O.; Miller, Thomas P.

In: Current Opinion in Oncology, Vol. 21, No. 5, 09.2009, p. 401-406.

Research output: Contribution to journalArticle

@article{d56bf299041f495fa6cc4532a3d05102,
title = "Localized large cell lymphoma: Is there any need for radiation therapy?",
abstract = "PURPOSE OF REVIEW: Diffuse large B-cell lymphoma is the most common lymphoma diagnosed in the United States and presents as localized disease in about 25{\%} of the patients. The standard of care was established by Southwest Oncology Group trial 8736, which showed the superiority of a short course of chemotherapy followed by radiation over a longer course of chemotherapy alone. This review discusses the studies that followed with the intent to establish whether the standard of care has changed. RECENT FINDINGS: Subsequent studies examined the role of radiation therapy, the number of cycles and intensity of chemotherapy, and addition of rituximab. Interpretation of results has been confounded by patient selection, especially by including patients with bulky stage II disease. Quality of radiation therapy may have diminished its efficacy in some of the studies. Concurrent administration of rituximab provided a more modest improvement as compared with advanced disease setting. Attempts are now made to use PET scans to eliminate the need for radiation therapy in some patients. SUMMARY: Radiation therapy remains useful when administered expediently and as initially described, but PET scans successfully define a subset of patients who do not benefit from radiation. Using a longer or more intensive course of rituximab-containing chemotherapy without radiation has never been compared to combined modality treatment and remains investigational.",
keywords = "Aggressive lymphoma, Diffuse large B-cell lymphoma, Early-stage, Localized, Radiation therapy",
author = "Persky, {Daniel O.} and Miller, {Thomas P}",
year = "2009",
month = "9",
doi = "10.1097/CCO.0b013e32832f3c8b",
language = "English (US)",
volume = "21",
pages = "401--406",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Localized large cell lymphoma

T2 - Is there any need for radiation therapy?

AU - Persky, Daniel O.

AU - Miller, Thomas P

PY - 2009/9

Y1 - 2009/9

N2 - PURPOSE OF REVIEW: Diffuse large B-cell lymphoma is the most common lymphoma diagnosed in the United States and presents as localized disease in about 25% of the patients. The standard of care was established by Southwest Oncology Group trial 8736, which showed the superiority of a short course of chemotherapy followed by radiation over a longer course of chemotherapy alone. This review discusses the studies that followed with the intent to establish whether the standard of care has changed. RECENT FINDINGS: Subsequent studies examined the role of radiation therapy, the number of cycles and intensity of chemotherapy, and addition of rituximab. Interpretation of results has been confounded by patient selection, especially by including patients with bulky stage II disease. Quality of radiation therapy may have diminished its efficacy in some of the studies. Concurrent administration of rituximab provided a more modest improvement as compared with advanced disease setting. Attempts are now made to use PET scans to eliminate the need for radiation therapy in some patients. SUMMARY: Radiation therapy remains useful when administered expediently and as initially described, but PET scans successfully define a subset of patients who do not benefit from radiation. Using a longer or more intensive course of rituximab-containing chemotherapy without radiation has never been compared to combined modality treatment and remains investigational.

AB - PURPOSE OF REVIEW: Diffuse large B-cell lymphoma is the most common lymphoma diagnosed in the United States and presents as localized disease in about 25% of the patients. The standard of care was established by Southwest Oncology Group trial 8736, which showed the superiority of a short course of chemotherapy followed by radiation over a longer course of chemotherapy alone. This review discusses the studies that followed with the intent to establish whether the standard of care has changed. RECENT FINDINGS: Subsequent studies examined the role of radiation therapy, the number of cycles and intensity of chemotherapy, and addition of rituximab. Interpretation of results has been confounded by patient selection, especially by including patients with bulky stage II disease. Quality of radiation therapy may have diminished its efficacy in some of the studies. Concurrent administration of rituximab provided a more modest improvement as compared with advanced disease setting. Attempts are now made to use PET scans to eliminate the need for radiation therapy in some patients. SUMMARY: Radiation therapy remains useful when administered expediently and as initially described, but PET scans successfully define a subset of patients who do not benefit from radiation. Using a longer or more intensive course of rituximab-containing chemotherapy without radiation has never been compared to combined modality treatment and remains investigational.

KW - Aggressive lymphoma

KW - Diffuse large B-cell lymphoma

KW - Early-stage

KW - Localized

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=69549135986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549135986&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32832f3c8b

DO - 10.1097/CCO.0b013e32832f3c8b

M3 - Article

C2 - 19593138

AN - SCOPUS:69549135986

VL - 21

SP - 401

EP - 406

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -